PDF(Pubmed)
Abstract：
Trastuzumab is the cornerstone treatment for HER2-positive breast cancer. While ocular side effects are more commonly described after the use of the antibody-drug conjugate ado-trastuzumab emtansine, we here describe corneal melting in a 79-year-old patient after three cycles of trastuzumab monotherapy. Signs and symptoms persisted with subsequent trastuzumab cycles. The patient showed improvement after treatment with intense lubrication, topical antibiotics, and topical steroids. After tapering of steroids, there was recurrence of epitheliopathy after subsequent trastuzumab treatment, which subsided upon restarting topical steroids. Finally, the patient was kept on a low-dose topical steroid regimen which prevented further epitheliopathy during the next trastuzumab cycles.
摘要：
曲妥珠单抗是HER2阳性乳腺癌的基础治疗方法。虽然在使用抗体-药物缀合物ado-曲妥珠单抗emtansine后更常见地描述眼部副作用，我们在此描述一名79岁的患者在接受三个周期的曲妥珠单抗单药治疗后的角膜融化.随后的曲妥珠单抗周期持续存在体征和症状。患者经过强烈润滑治疗后表现出改善，局部抗生素，和局部类固醇。类固醇逐渐减少后，后续曲妥珠单抗治疗后上皮病变复发,重新启动局部类固醇后消退。最后,在下一个曲妥珠单抗周期期间,患者继续接受低剂量局部类固醇方案,该方案可防止进一步的上皮病变.
